Roquette Showcases Scalable Drug Delivery Innovations at CPHI China 2026

10.6.2026 09:00:00 CEST | Business Wire | Press Release

Roquette, a global leader in plant-based ingredients and pharmaceutical excipients, will showcase its comprehensive portfolio of innovative drug delivery solutions at CPHI & PMEC China 2026, taking place June 16-18 at the Shanghai New International Expo Centre (SNIEC). Under the theme “One Roquette for Innovations,” Roquette’s Health & Pharma Solutions Business Unit will exhibit at booth E3D26, highlighting how its deep scientific expertise and technical capabilities enable pharmaceutical companies to turn promising formulations into scalable commercial realities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610596225/en/

Visit Roquette at booth E3D26 to meet with its team of experts

“As the pharmaceutical industry accelerates innovation, from GLP-1 therapies to complex biologics, the pressure to deliver manufacturing reliability, consistent supply, and robust formulations at scale has never been greater,” said Angela Strzelecki, Senior Vice President of the Roquette Group and CEO of Roquette’s Health & Pharma Solutions Business Unit. “At Roquette, we are uniquely positioned to address these challenges through our integrated portfolio spanning excipients, formulation technologies, biopharmaceutical solutions, and hard capsules. With a wide manufacturing network and global quality standards, we are committed to being the trusted partner that powers the next generation of drug delivery in China and the Asia Pacific region.”

PEARLITOL^® Mannitol: Enabling Scalable, Modern Drug Delivery

Roquette’s PEARLITOL^® mannitol, a versatile excipient designed to simplify formulation development while maintaining exceptional performance at scale, will be showcased at the booth. Manufactured in China to support reliable regional supply, PEARLITOL^® mannitol enables:

High and low dose formulations across a wide range of dosage forms
Enhanced stability in sensitive conditions
Reliable processability and batch-to-batch consistency
Flexibility across oral, injectable, inhalation, and biologic applications

Integrated Solutions for Every Stage of Drug Development

Roquette’s booth will feature its complete range of pharmaceutical solutions designed to address the industry's most pressing challenges:
High-performance pharmaceutical excipients: including Avicel^® microcrystalline cellulose, Ac-Di-Sol^® croscarmellose sodium, METHOCEL™ HPMC, ETHOCEL™ ethylcellulose, and POLYOX™ polyethylene oxide
Differentiated formulation technologies: across oral solid dosage forms, controlled release systems, and complex specialty formulations
Biopharmaceutical solutions: including KLEPTOSE^® beta-cyclodextrins for protein stabilization and NOVAMATRIX-3D™ alginate foams for 3D cell culture
Hard capsules and integrated delivery solutions: Qualicaps by Roquette offers a full range of HPMC and gelatin capsules for oral and inhalation applications
End-to-end support: expertise spanning from early formulation development to commercial manufacturing scale-up

Connect with Roquette at CPHI China 2026

Visit Roquette at booth E3D26 to meet with its team of experts and learn how its integrated solutions can help you overcome formulation complexity and scaling challenges. For more information about Roquette's participation at CPHI China 2026, click here.

About Roquette

Roquette is a global leader in sustainable plant-based solutions, driving innovation and strong partnerships that are shaping the future of nutrition, health, and bioindustry.

The company harnesses natural resources such as wheat, corn, seaweed, and cellulose to craft high-performance ingredients used in everyday foods, oral medications, advanced biopharmaceuticals, and a range of bio-based products.

A family-owned company with over 90 years of expertise and 11,000 employees, Roquette serves clients in over 150 countries and is committed to creating lasting value for customers, patients, consumers, and society.

Together, we turn the potential of nature into the essentials of life.

Discover more about Roquette here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610596225/en/

Contacts

Press Contact
Lisa Luke
Global Head of Communications
Roquette’s Health & Pharma Solutions Business Unit
Email: lisa.luke@roquette.com

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Introduces BlueVerse™ Currency to Enable Outcome-Based Pricing in the Agentic AI Era10.6.2026 10:30:00 CEST | Press Release

LTM, the Business Creativity partner to the world’s largest enterprises, today introduced BlueVerse™ Currency, an AI-linked commercial model that prices enterprise work by outcomes rather than effort consumed as enterprises scale agentic AI across core processes. BlueVerse Currency brings together the full BlueVerse stack—People (expertise on demand), Accelerators (reusable assets that speed delivery), Agents (autonomous AI workforce), Platforms (orchestration layer to scale delivery), and Tokens (compute and model usage)—into a single commercial construct. It introduces outcome-linked pricing tied to measurable business results, enabling shared productivity gains so clients can capture AI-driven efficiency value. The model also supports fungible resourcing, enabling reallocation mid-contract to evolving priorities, and faster reinvestment, with savings redirected into innovation. It is underpinned by a hybrid structure with fixed and variable pricing components, supported by use-case–

Smead Capital Management Extends International Value Strategy to Global Investors Through New Fund10.6.2026 09:00:00 CEST | Press Release

Smead Capital Management, a Phoenix-based investment management firm and a leader in value investing, today announced the launch of the Smead Global ex-US Value UCITS Fund designed to provide global investors with access to a product modeled after the firm’s long-standing Smead International Value Strategy. The Smead Global ex-US Value UCITS Fund is domiciled in Luxembourg. Investors can access the fund through Smead Capital Management’s website and it is available to professional and qualified investors through the fund’s transfer agent. The strategy that the Smead Global ex-US Value UCITS Fund is modeled after, the Smead International Value Strategy, has been a core contributor to Smead Capital Management’s outstanding performance for over a decade. Like all Smead products, the Global ex-US Value UCITS Fund will be built on Smead’s eight investment criteria and a disciplined, contrarian, value approach. “Many investors around the world believe non-US companies cannot produce attracti

Dodge Opens Orders for the Next Generation Charger in Europe10.6.2026 09:00:00 CEST | Press Release

An Icon Enters Its Next Generation This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609386800/en/ Celebrating its 60th anniversary this year, Dodge opens a bold new chapter in Europe with the launch of the next-generation Dodge Charger, bringing one of America’s most iconic muscle cars back to European roads through a new multi-energy lineup engineered to deliver performance and attitude without compromise. Six decades after the original Charger helped define the muscle car era, this new eighth-generation model evolves the formula for a new generation of drivers while remaining unmistakably Dodge in character, design and presence. Available with both all-electric and gasoline powertrains, the new Charger reflects Dodge’s performance-first philosophy: different powertrains, same muscle car DNA. The next-generation Charger arrives in Europe in both two-door and four-door configurations, combining iconic proportions, wide-body

Trustd Brings Know Your Carrier to Market as Freight Fraud Costs European Supply Chains Over €1bn10.6.2026 08:01:00 CEST | Press Release

Trustd, the digital identity and credentials verification platform for transport and logistics, is bringing to market Know Your Carrier (KYC), a web-based verification tool that lets shippers and 3PLs get an instant risk signal on carriers quoting for work via email in seconds. Cargo crime across EMEA has risen 438% in three years. More than 108,000 supply chain thefts were recorded across the region in the last two years. Of the 5% that reported a financial loss, the combined value exceeded €1bn, equivalent to €1.3m every 24 hours. Know Your Carrier draws on Trustd's expertise in digital identity verification to address a problem that has until now had no industry-wide solution. The web-based tool plugs into existing workflows with no installation or integration. Users enter an email address and, where available, a VAT number. The tool checks email legitimacy and domain matching, business registration data, adverse media, sanctions and court judgments, and Trustd’s own growing network

Sofinnova Partners Launches Collaboration with AWS to Scale AI Across Life Sciences Innovation10.6.2026 08:00:00 CEST | Press Release

Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced a collaboration with Amazon Web Services (AWS), to embed AI more deeply across its investment platform and portfolio companies. The collaboration supports Sofinnova.AI, the firm’s initiative to integrate AI across its core activities, from sourcing and evaluating investments to supporting company building. At the center of this effort is Sofia, Sofinnova's proprietary AI platform, which will be extended beyond internal use to include a founder-facing version. Through this collaboration, Sofinnova-backed startups will gain access to tailored AWS resources and technical enablement, helping them move faster from early research to development and commercialization. “AI is becoming central to how new therapies are discovered, developed, and brought to patients,” said Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners. “With Sofinnova.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom